샘플 요청 목록

 카트 문의
시장보고서
상품코드
1792743

세계의 신경학 임상시험수탁기관 시장

Neurology Contract Research Organization
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 497 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

신경학 임상시험수탁기관 세계 시장은 2030년까지 117억 달러에 달할 전망

2024년에 82억 달러로 추정되는 신경학 임상시험수탁기관 세계 시장은 2024년부터 2030년까지 CAGR 6.0%로 성장하여 2030년에는 117억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 임상 서비스는 CAGR 7.0%를 기록하며 분석 기간 종료시에는 35억 달러에 달할 것으로 예측됩니다. 데이터 관리 서비스 분야의 성장률은 분석 기간 동안 CAGR 6.7%로 추정됩니다.

미국 시장은 22억 달러, 중국은 CAGR 9.7%로 성장할 것으로 예측

미국의 신경학 임상시험수탁기관 시장은 2024년에 22억 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2024년부터 2030년 분석 기간 동안 CAGR 9.7%로 성장하여 2030년에는 24억 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 2.9%와 6.0%로 예측됩니다. 유럽에서는 독일이 CAGR 4.0%로 성장할 것으로 예측됩니다.

세계의 신경학 임상시험수탁기관(CRO) 시장 - 주요 동향과 촉진요인 정리

신경학 전문 CRO가 의약품 개발에 필수적인 이유는 무엇일까?

신경학 전문 의약품 개발 수탁기관(CRO)은 중추신경계(CNS) 질환의 연구개발 라이프사이클 전반에 걸쳐 제약 및 바이오테크놀러지 기업을 지원하는 데 중요한 역할을 하고 있습니다. 이들 CRO는 알츠하이머병, 파킨슨병, 다발성 경화증, 간질, 희귀신경근육질환 등 복잡한 신경질환에 맞춘 전임상 및 임상시험 수행에 특화된 역량을 보유하고 있습니다. 신경계 의약품 개발은 실패율이 높고 일정이 길기 때문에 CRO에 아웃소싱을 통해 프로세스 간소화, 비용 절감, 시험 설계의 정확성 향상에 도움이 됩니다.

신경계 CRO는 숙련된 임상시험책임자, 환자 모집 네트워크, 신경영상 진단 전문성, 중추신경계 약물 경로에 대한 규제 전략에 대한 접근성을 제공합니다. CRO의 참여는 질병의 이질성, 위약 반응, 진행 지연으로 인해 평가변수 측정이 복잡해지는 초기 단계의 임상시험에서 특히 중요합니다. 이들 조직은 프로토콜 설계, 데이터 관리, 신경특이적 바이오마커를 다루며, 스폰서가 핵심 연구에 집중할 수 있도록 지역 및 세계 표준을 준수하면서 핵심 연구에 집중할 수 있도록 돕습니다.

기술 통합은 신경 CRO의 역량을 어떻게 향상시키고 있는가?

디지털 전환은 신경학 CRO의 업무 효율성과 분석력을 크게 향상시켰습니다. 첨단 신경영상 플랫폼, 머신러닝 기반 인지 평가 도구, 웨어러블 신경 모니터링 기기가 시험 프로토콜에 통합되고 있습니다. 이러한 도구들은 환자의 행동, 증상 패턴, 치료 반응에 대한 보다 상세한 실시간 데이터 수집에 도움을 주고 있습니다. 또한, 원격 모니터링 기술은 신경 퇴행성 질환 연구에서 흔히 볼 수 있는 장기적인 시험의 연속성을 향상시킵니다.

인공지능과 예측 분석은 최적의 임상시험 실시기관 선정, 모집 시기 예측, 전자의무기록, 뇌 스캔, 생체 시료 등 다양한 데이터세트 분석에 활용되고 있습니다. 전자 데이터 수집 시스템과 중앙 집중식 모니터링의 통합을 통해 신경과 CRO는 분산형 또는 하이브리드형 시험 모델을 지원하여 다양한 지역의 참가자에 대한 접근성을 확대할 수 있습니다. 이러한 디지털 기능은 적응증 시험이나 희귀질환 코호트를 필요로 하는 시험 등 복잡한 시험 설계에 필수적입니다.

스폰서가 신경학 시험의 아웃소싱을 추진하는 요인은 무엇인가?

신경학 분야의 아웃소싱이 증가하는 배경에는 스폰서가 직면한 몇 가지 과학적 및 운영상의 문제가 있습니다. 질병 진행에 대한 큰 편차, 유효한 바이오마커의 부재, 규제 당국의 변화하는 기대치 등으로 인해 신경학 시험의 자체 관리는 자원 집약적일 수밖에 없습니다. CRO는 전임상 모델링 및 IND 획득 가능 시험부터 임상시험 실시기관 선정, 환자 레지스트리 개발, 시판 후 조사까지 엔드투엔드 지원을 제공합니다. 신경학, 생물통계학, 영상 진단, 약물감시 전문성을 갖춘 다학제적 팀을 제공할 수 있는 CRO의 능력은 임상시험의 라이프사이클 전반에 걸쳐 가치를 높입니다.

임상시험의 세계화도 신경학 분야의 CRO 서비스에 대한 수요 증가에 기여하고 있습니다. 여러 국가에 걸쳐 임상시험을 진행함으로써, 특히 희귀한 중추신경계 질환의 경우, 다양한 환자 대표성을 확보하고 더 많은 참여자 풀에 접근할 수 있습니다. 세계 인프라를 갖추고 치료와 연계된 CRO는 이러한 시험을 관리하고, 각국의 규제 상황을 파악하며, 지역 간 표준화된 데이터를 확보하는 데 있어 바람직한 파트너입니다. CRO 간의 합병, 제휴, 플랫폼 확장은 이 분야의 경쟁과 역량을 더욱 재편하고 있습니다.

신경학 위탁 연구 기관 시장의 성장은 몇 가지 요인에 의해 이루어집니다.

특히 알츠하이머, ALS, 다발성 경화증 등 신경계 신약개발에 대한 투자가 증가하고 있어 중추신경계 전문 CRO에 대한 수요가 증가하고 있습니다. 임상시험 프로토콜의 복잡성, 규제 당국의 감시 강화, 장기적인 안전성 및 인지 기능 추적의 필요성은 스폰서들이 외부 전문가의 도움을 받도록 유도하고 있습니다. 디지털 바이오마커, 모바일 헬스 툴, 비중앙집중형 임상시험 형태의 출현으로 CRO는 보다 통합적이고 기술적으로 효과적인 솔루션을 제공해야 합니다. 신경질환의 유병률이 확대되고 의약품 개발 기간 단축이 요구됨에 따라 효율적이고 경험이 풍부하며 전 세계 네트워크를 갖춘 CRO에 대한 수요가 증가하고 있습니다. 제약기업과 신경계 CRO의 협력체계 또한 기술 혁신을 가속화하고 CNS 연구 범위를 전 세계적으로 확대하고 있습니다.

부문

서비스(임상 서비스, 데이터 관리 서비스, 의약품 안전성, 메디컬 및 사이언티픽 라이팅, 약사, 약리학 및 독성학, 품질 및 컴플라이언스), 시험(신경과학 포커스 시험, 신경학 포커스 시험), 적응증(알츠하이머병 적응증, 뇌종양 적응증, 간질·경련 적응증, 정신분열증 적응증, 다발성 경화증 적응증, 근 디스트로피 적응증, 뇌졸중 적응증, 기타 적응증), 최종사용자(제약·바이오의약품 기업 최종사용자, 의료기기 기업 최종사용자, 학술·연구기관 최종사용자)

조사 대상 기업 사례

  • Alimentiv Inc.
  • Axon CRO
  • Atlantic Research Group, Inc.
  • Charles River Laboratories
  • CTI Clinical Trial & Consulting
  • EphyX Neuroscience
  • Ergomed plc
  • Fortrea Holdings Inc.(formerly Covance/Labcorp Drug Development)
  • ICON plc
  • IQVIA Inc.
  • Labcorp Drug Development
  • MD Biosciences
  • Medpace Holdings, Inc.
  • Neuroservices-Alliance
  • Neuron Experts
  • Parexel International Corporation
  • Pharmaron Beijing Co., Ltd.
  • PPD Inc.(Thermo Fisher Scientific)
  • QPS Neuropharmacology
  • Syneos Health
  • WuXi AppTec

AI 통합

Global Industry Analysts는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 일반적인 LLM 및 업계별 SLM 쿼리를 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSM 25.08.27

Global Neurology Contract Research Organization Market to Reach US$11.7 Billion by 2030

The global market for Neurology Contract Research Organization estimated at US$8.2 Billion in the year 2024, is expected to reach US$11.7 Billion by 2030, growing at a CAGR of 6.0% over the analysis period 2024-2030. Clinical Services, one of the segments analyzed in the report, is expected to record a 7.0% CAGR and reach US$3.5 Billion by the end of the analysis period. Growth in the Data Management Services segment is estimated at 6.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.2 Billion While China is Forecast to Grow at 9.7% CAGR

The Neurology Contract Research Organization market in the U.S. is estimated at US$2.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.4 Billion by the year 2030 trailing a CAGR of 9.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.9% and 6.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.0% CAGR.

Global Neurology Contract Research Organization (CRO) Market - Key Trends & Drivers Summarized

Why Are Neurology-Focused CROs Becoming Indispensable in Drug Development?

Neurology-focused Contract Research Organizations (CROs) play a vital role in supporting pharmaceutical and biotechnology companies throughout the drug development lifecycle for central nervous system (CNS) disorders. These CROs bring specialized capabilities in conducting preclinical and clinical trials tailored to complex neurological conditions, such as Alzheimer’s, Parkinson’s, multiple sclerosis, epilepsy, and rare neuromuscular diseases. Given the high failure rate and extended timelines of neurology drug development, outsourcing to CROs helps streamline processes, reduce costs, and improve trial design precision.

Neurology CROs offer access to experienced clinical investigators, patient recruitment networks, neuroimaging expertise, and regulatory strategy tailored to CNS drug pathways. Their involvement is particularly crucial in early-phase trials where disease heterogeneity, placebo response, and slow progression complicate endpoint measurement. By handling protocol design, data management, and neuro-specific biomarkers, these organizations allow sponsors to focus on core research while ensuring compliance with regional and global standards.

How Are Technological Integrations Enhancing Neurology CRO Capabilities?

Digital transformation has significantly improved the operational efficiency and analytical strength of neurology CROs. Advanced neuroimaging platforms, machine learning-based cognitive assessment tools, and wearable neuro-monitoring devices are increasingly embedded into study protocols. These tools help collect more granular and real-time data on patient behavior, symptom patterns, and treatment response. Remote monitoring technologies also enhance retention in long-duration trials, which are common in neurodegenerative disease research.

Artificial intelligence and predictive analytics are being used to identify optimal trial sites, forecast recruitment timelines, and analyze diverse data sets from electronic health records, brain scans, and biospecimens. Integration of electronic data capture systems with centralized monitoring allows neurology CROs to support decentralized or hybrid trial models, expanding access to participants in different geographies. These digital capabilities are essential for complex trial designs, such as adaptive trials and those requiring rare disease cohorts.

What Factors Are Driving Sponsors to Outsource More Neurology Trials?

Outsourcing in neurology is increasing due to several scientific and operational challenges that sponsors face. High variability in disease progression, lack of validated biomarkers, and evolving regulatory expectations make in-house management of neurology trials resource-intensive. CROs provide end-to-end support from preclinical modeling and IND-enabling studies to site selection, patient registry development, and post-marketing surveillance. Their ability to offer multidisciplinary teams with expertise in neurology, biostatistics, imaging, and pharmacovigilance adds value across the study lifecycle.

Globalization of trials has also contributed to the growing demand for CRO services in neurology. Conducting studies across multiple countries ensures diverse patient representation and access to larger participant pools, especially for rare CNS disorders. CROs with global infrastructure and therapeutic alignment are preferred partners for managing such trials, navigating local regulatory landscapes, and ensuring standardized data across regions. Mergers, partnerships, and platform expansions among CROs are further reshaping competition and capabilities in this space.

Growth in the neurology contract research organization market is driven by several factors.

Rising investment in neurological drug discovery, especially in Alzheimer’s, ALS, and multiple sclerosis, is fueling demand for specialized CROs with proven CNS expertise. Increasing complexity of clinical trial protocols, growing regulatory scrutiny, and the need for long-term safety and cognitive function tracking are encouraging sponsors to seek expert external support. Emergence of digital biomarkers, mobile health tools, and decentralized trial formats is prompting CROs to offer more integrated and technologically enabled solutions. Expanding prevalence of neurological disorders and the push for faster drug development timelines have created sustained demand for efficient, experienced, and globally networked CROs. Collaborative efforts between pharmaceutical firms and neurology CROs are also accelerating innovation and expanding the scope of CNS research worldwide.

SCOPE OF STUDY:

The report analyzes the Neurology Contract Research Organization market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Service (Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology, Quality & Compliance); Study (Neuroscience Focused Study, Neurology Focused Study); Indication (Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication, Other Indications); End-Use (Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use, Academic & Research Institutes End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • Alimentiv Inc.
  • Axon CRO
  • Atlantic Research Group, Inc.
  • Charles River Laboratories
  • CTI Clinical Trial & Consulting
  • EphyX Neuroscience
  • Ergomed plc
  • Fortrea Holdings Inc. (formerly Covance/Labcorp Drug Development)
  • ICON plc
  • IQVIA Inc.
  • Labcorp Drug Development
  • MD Biosciences
  • Medpace Holdings, Inc.
  • Neuroservices-Alliance
  • Neuron Experts
  • Parexel International Corporation
  • Pharmaron Beijing Co., Ltd.
  • PPD Inc. (Thermo Fisher Scientific)
  • QPS Neuropharmacology
  • Syneos Health
  • WuXi AppTec

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Neurology Contract Research Organization - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Outsourcing of Neurology Trials Drives Growth for Specialized CRO Services
    • Increasing Complexity of CNS Drug Development Strengthens Business Case for Neurology-Focused CROs
    • Growing Demand for Rare and Orphan Neurological Disorder Studies Expands Niche CRO Opportunities
    • Shift Toward Decentralized Clinical Trials Spurs Adoption of Tech-Enabled Neurology CRO Models
    • High Failure Rates in CNS Drug Trials Drive Reliance on Specialized Clinical Expertise
    • Use of AI and Digital Biomarkers in Trial Design Accelerates Innovation in Neurology CROs
    • Pharmaceutical and Biotech Companies Increasingly Leverage CROs for Global Neurology Trials
    • Emergence of Novel Neuromodulation Therapies Generates Demand for Customized CRO Support
    • Rising Focus on Early-Phase CNS Trials Expands Scope for Preclinical Neurology CRO Services
    • Demand for Biomarker-Driven CNS Studies Propels Integration of Imaging and Molecular CRO Capabilities
    • Increasing Regulatory Scrutiny on Neurology Trials Enhances Demand for Experienced CRO Partners
    • Patient Recruitment and Retention Challenges in CNS Studies Drive Use of Patient-Centric CRO Strategies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Neurology Contract Research Organization Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Neurology Contract Research Organization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Neurology Contract Research Organization by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Clinical Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Clinical Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Clinical Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Data Management Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Data Management Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Data Management Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Drug Safety by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Drug Safety by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Drug Safety by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Medical & Scientific Writing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Medical & Scientific Writing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Medical & Scientific Writing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Regulatory Affairs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Regulatory Affairs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Regulatory Affairs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Pharmacology & Toxicology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Pharmacology & Toxicology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Pharmacology & Toxicology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Quality & Compliance by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Quality & Compliance by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Quality & Compliance by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Alzheimer's Disease Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Alzheimer's Disease Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Alzheimer's Disease Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Brain Tumor Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Brain Tumor Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Brain Tumor Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Epilepsy & Seizures Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Epilepsy & Seizures Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: World 16-Year Perspective for Epilepsy & Seizures Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Schizophrenia Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Schizophrenia Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: World 16-Year Perspective for Schizophrenia Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Multiple Sclerosis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Multiple Sclerosis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: World 16-Year Perspective for Multiple Sclerosis Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Muscular Dystrophy Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Muscular Dystrophy Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: World 16-Year Perspective for Muscular Dystrophy Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Stroke Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: World Historic Review for Stroke Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: World 16-Year Perspective for Stroke Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 47: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 48: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: World 16-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 50: World Recent Past, Current & Future Analysis for Pharma & Biopharma Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: World Historic Review for Pharma & Biopharma Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: World 16-Year Perspective for Pharma & Biopharma Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 53: World Recent Past, Current & Future Analysis for Medical Device Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: World Historic Review for Medical Device Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: World 16-Year Perspective for Medical Device Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 56: World Recent Past, Current & Future Analysis for Academic & Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 57: World Historic Review for Academic & Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: World 16-Year Perspective for Academic & Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 59: World Recent Past, Current & Future Analysis for Neuroscience Focused Study by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 60: World Historic Review for Neuroscience Focused Study by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: World 16-Year Perspective for Neuroscience Focused Study by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 62: World Recent Past, Current & Future Analysis for Neurology Focused Study by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 63: World Historic Review for Neurology Focused Study by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: World 16-Year Perspective for Neurology Focused Study by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Neurology Contract Research Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 65: USA Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: USA Historic Review for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: USA 16-Year Perspective for Neurology Contract Research Organization by Service - Percentage Breakdown of Value Sales for Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance for the Years 2014, 2025 & 2030
    • TABLE 68: USA Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Indication - Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: USA Historic Review for Neurology Contract Research Organization by Indication - Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: USA 16-Year Perspective for Neurology Contract Research Organization by Indication - Percentage Breakdown of Value Sales for Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 71: USA Recent Past, Current & Future Analysis for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: USA Historic Review for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: USA 16-Year Perspective for Neurology Contract Research Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 74: USA Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: USA Historic Review for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: USA 16-Year Perspective for Neurology Contract Research Organization by Study - Percentage Breakdown of Value Sales for Neuroscience Focused Study and Neurology Focused Study for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 77: Canada Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Canada Historic Review for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Canada 16-Year Perspective for Neurology Contract Research Organization by Service - Percentage Breakdown of Value Sales for Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance for the Years 2014, 2025 & 2030
    • TABLE 80: Canada Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Indication - Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Canada Historic Review for Neurology Contract Research Organization by Indication - Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Canada 16-Year Perspective for Neurology Contract Research Organization by Indication - Percentage Breakdown of Value Sales for Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 83: Canada Recent Past, Current & Future Analysis for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Canada Historic Review for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Canada 16-Year Perspective for Neurology Contract Research Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 86: Canada Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Canada Historic Review for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Canada 16-Year Perspective for Neurology Contract Research Organization by Study - Percentage Breakdown of Value Sales for Neuroscience Focused Study and Neurology Focused Study for the Years 2014, 2025 & 2030
  • JAPAN
    • Neurology Contract Research Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 89: Japan Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Japan Historic Review for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Japan 16-Year Perspective for Neurology Contract Research Organization by Service - Percentage Breakdown of Value Sales for Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance for the Years 2014, 2025 & 2030
    • TABLE 92: Japan Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Indication - Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Japan Historic Review for Neurology Contract Research Organization by Indication - Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Japan 16-Year Perspective for Neurology Contract Research Organization by Indication - Percentage Breakdown of Value Sales for Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 95: Japan Recent Past, Current & Future Analysis for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Japan Historic Review for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Japan 16-Year Perspective for Neurology Contract Research Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 98: Japan Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Japan Historic Review for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Japan 16-Year Perspective for Neurology Contract Research Organization by Study - Percentage Breakdown of Value Sales for Neuroscience Focused Study and Neurology Focused Study for the Years 2014, 2025 & 2030
  • CHINA
    • Neurology Contract Research Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 101: China Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: China Historic Review for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: China 16-Year Perspective for Neurology Contract Research Organization by Service - Percentage Breakdown of Value Sales for Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance for the Years 2014, 2025 & 2030
    • TABLE 104: China Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Indication - Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: China Historic Review for Neurology Contract Research Organization by Indication - Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: China 16-Year Perspective for Neurology Contract Research Organization by Indication - Percentage Breakdown of Value Sales for Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 107: China Recent Past, Current & Future Analysis for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: China Historic Review for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: China 16-Year Perspective for Neurology Contract Research Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 110: China Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: China Historic Review for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: China 16-Year Perspective for Neurology Contract Research Organization by Study - Percentage Breakdown of Value Sales for Neuroscience Focused Study and Neurology Focused Study for the Years 2014, 2025 & 2030
  • EUROPE
    • Neurology Contract Research Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 113: Europe Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 114: Europe Historic Review for Neurology Contract Research Organization by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: Europe 16-Year Perspective for Neurology Contract Research Organization by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 116: Europe Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Europe Historic Review for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: Europe 16-Year Perspective for Neurology Contract Research Organization by Service - Percentage Breakdown of Value Sales for Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance for the Years 2014, 2025 & 2030
    • TABLE 119: Europe Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Indication - Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Europe Historic Review for Neurology Contract Research Organization by Indication - Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: Europe 16-Year Perspective for Neurology Contract Research Organization by Indication - Percentage Breakdown of Value Sales for Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 122: Europe Recent Past, Current & Future Analysis for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Europe Historic Review for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: Europe 16-Year Perspective for Neurology Contract Research Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 125: Europe Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Europe Historic Review for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: Europe 16-Year Perspective for Neurology Contract Research Organization by Study - Percentage Breakdown of Value Sales for Neuroscience Focused Study and Neurology Focused Study for the Years 2014, 2025 & 2030
  • FRANCE
    • Neurology Contract Research Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 128: France Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: France Historic Review for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: France 16-Year Perspective for Neurology Contract Research Organization by Service - Percentage Breakdown of Value Sales for Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance for the Years 2014, 2025 & 2030
    • TABLE 131: France Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Indication - Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: France Historic Review for Neurology Contract Research Organization by Indication - Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: France 16-Year Perspective for Neurology Contract Research Organization by Indication - Percentage Breakdown of Value Sales for Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 134: France Recent Past, Current & Future Analysis for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: France Historic Review for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: France 16-Year Perspective for Neurology Contract Research Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 137: France Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: France Historic Review for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: France 16-Year Perspective for Neurology Contract Research Organization by Study - Percentage Breakdown of Value Sales for Neuroscience Focused Study and Neurology Focused Study for the Years 2014, 2025 & 2030
  • GERMANY
    • Neurology Contract Research Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 140: Germany Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Germany Historic Review for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Germany 16-Year Perspective for Neurology Contract Research Organization by Service - Percentage Breakdown of Value Sales for Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance for the Years 2014, 2025 & 2030
    • TABLE 143: Germany Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Indication - Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Germany Historic Review for Neurology Contract Research Organization by Indication - Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Germany 16-Year Perspective for Neurology Contract Research Organization by Indication - Percentage Breakdown of Value Sales for Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 146: Germany Recent Past, Current & Future Analysis for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Germany Historic Review for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Germany 16-Year Perspective for Neurology Contract Research Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 149: Germany Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Germany Historic Review for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Germany 16-Year Perspective for Neurology Contract Research Organization by Study - Percentage Breakdown of Value Sales for Neuroscience Focused Study and Neurology Focused Study for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 152: Italy Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Italy Historic Review for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Italy 16-Year Perspective for Neurology Contract Research Organization by Service - Percentage Breakdown of Value Sales for Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance for the Years 2014, 2025 & 2030
    • TABLE 155: Italy Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Indication - Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Italy Historic Review for Neurology Contract Research Organization by Indication - Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Italy 16-Year Perspective for Neurology Contract Research Organization by Indication - Percentage Breakdown of Value Sales for Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 158: Italy Recent Past, Current & Future Analysis for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Italy Historic Review for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Italy 16-Year Perspective for Neurology Contract Research Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 161: Italy Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Italy Historic Review for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Italy 16-Year Perspective for Neurology Contract Research Organization by Study - Percentage Breakdown of Value Sales for Neuroscience Focused Study and Neurology Focused Study for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Neurology Contract Research Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 164: UK Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: UK Historic Review for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: UK 16-Year Perspective for Neurology Contract Research Organization by Service - Percentage Breakdown of Value Sales for Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance for the Years 2014, 2025 & 2030
    • TABLE 167: UK Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Indication - Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: UK Historic Review for Neurology Contract Research Organization by Indication - Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: UK 16-Year Perspective for Neurology Contract Research Organization by Indication - Percentage Breakdown of Value Sales for Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 170: UK Recent Past, Current & Future Analysis for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: UK Historic Review for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: UK 16-Year Perspective for Neurology Contract Research Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 173: UK Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: UK Historic Review for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: UK 16-Year Perspective for Neurology Contract Research Organization by Study - Percentage Breakdown of Value Sales for Neuroscience Focused Study and Neurology Focused Study for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 176: Spain Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Spain Historic Review for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Spain 16-Year Perspective for Neurology Contract Research Organization by Service - Percentage Breakdown of Value Sales for Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance for the Years 2014, 2025 & 2030
    • TABLE 179: Spain Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Indication - Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Spain Historic Review for Neurology Contract Research Organization by Indication - Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Spain 16-Year Perspective for Neurology Contract Research Organization by Indication - Percentage Breakdown of Value Sales for Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 182: Spain Recent Past, Current & Future Analysis for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Spain Historic Review for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Spain 16-Year Perspective for Neurology Contract Research Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 185: Spain Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Spain Historic Review for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Spain 16-Year Perspective for Neurology Contract Research Organization by Study - Percentage Breakdown of Value Sales for Neuroscience Focused Study and Neurology Focused Study for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 188: Russia Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Russia Historic Review for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Russia 16-Year Perspective for Neurology Contract Research Organization by Service - Percentage Breakdown of Value Sales for Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance for the Years 2014, 2025 & 2030
    • TABLE 191: Russia Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Indication - Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Russia Historic Review for Neurology Contract Research Organization by Indication - Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Russia 16-Year Perspective for Neurology Contract Research Organization by Indication - Percentage Breakdown of Value Sales for Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 194: Russia Recent Past, Current & Future Analysis for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Russia Historic Review for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Russia 16-Year Perspective for Neurology Contract Research Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 197: Russia Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Russia Historic Review for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Russia 16-Year Perspective for Neurology Contract Research Organization by Study - Percentage Breakdown of Value Sales for Neuroscience Focused Study and Neurology Focused Study for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 200: Rest of Europe Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Europe Historic Review for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Europe 16-Year Perspective for Neurology Contract Research Organization by Service - Percentage Breakdown of Value Sales for Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance for the Years 2014, 2025 & 2030
    • TABLE 203: Rest of Europe Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Indication - Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Europe Historic Review for Neurology Contract Research Organization by Indication - Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Rest of Europe 16-Year Perspective for Neurology Contract Research Organization by Indication - Percentage Breakdown of Value Sales for Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 206: Rest of Europe Recent Past, Current & Future Analysis for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Europe Historic Review for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Rest of Europe 16-Year Perspective for Neurology Contract Research Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 209: Rest of Europe Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Rest of Europe Historic Review for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Rest of Europe 16-Year Perspective for Neurology Contract Research Organization by Study - Percentage Breakdown of Value Sales for Neuroscience Focused Study and Neurology Focused Study for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Neurology Contract Research Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 212: Asia-Pacific Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 213: Asia-Pacific Historic Review for Neurology Contract Research Organization by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 214: Asia-Pacific 16-Year Perspective for Neurology Contract Research Organization by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 215: Asia-Pacific Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Asia-Pacific Historic Review for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 217: Asia-Pacific 16-Year Perspective for Neurology Contract Research Organization by Service - Percentage Breakdown of Value Sales for Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance for the Years 2014, 2025 & 2030
    • TABLE 218: Asia-Pacific Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Indication - Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Asia-Pacific Historic Review for Neurology Contract Research Organization by Indication - Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 220: Asia-Pacific 16-Year Perspective for Neurology Contract Research Organization by Indication - Percentage Breakdown of Value Sales for Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 221: Asia-Pacific Recent Past, Current & Future Analysis for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Asia-Pacific Historic Review for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 223: Asia-Pacific 16-Year Perspective for Neurology Contract Research Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 224: Asia-Pacific Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Asia-Pacific Historic Review for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 226: Asia-Pacific 16-Year Perspective for Neurology Contract Research Organization by Study - Percentage Breakdown of Value Sales for Neuroscience Focused Study and Neurology Focused Study for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Neurology Contract Research Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 227: Australia Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Australia Historic Review for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 229: Australia 16-Year Perspective for Neurology Contract Research Organization by Service - Percentage Breakdown of Value Sales for Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance for the Years 2014, 2025 & 2030
    • TABLE 230: Australia Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Indication - Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Australia Historic Review for Neurology Contract Research Organization by Indication - Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 232: Australia 16-Year Perspective for Neurology Contract Research Organization by Indication - Percentage Breakdown of Value Sales for Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 233: Australia Recent Past, Current & Future Analysis for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Australia Historic Review for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 235: Australia 16-Year Perspective for Neurology Contract Research Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 236: Australia Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Australia Historic Review for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 238: Australia 16-Year Perspective for Neurology Contract Research Organization by Study - Percentage Breakdown of Value Sales for Neuroscience Focused Study and Neurology Focused Study for the Years 2014, 2025 & 2030
  • INDIA
    • Neurology Contract Research Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 239: India Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: India Historic Review for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 241: India 16-Year Perspective for Neurology Contract Research Organization by Service - Percentage Breakdown of Value Sales for Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance for the Years 2014, 2025 & 2030
    • TABLE 242: India Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Indication - Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: India Historic Review for Neurology Contract Research Organization by Indication - Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 244: India 16-Year Perspective for Neurology Contract Research Organization by Indication - Percentage Breakdown of Value Sales for Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 245: India Recent Past, Current & Future Analysis for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: India Historic Review for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 247: India 16-Year Perspective for Neurology Contract Research Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 248: India Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: India Historic Review for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 250: India 16-Year Perspective for Neurology Contract Research Organization by Study - Percentage Breakdown of Value Sales for Neuroscience Focused Study and Neurology Focused Study for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 251: South Korea Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: South Korea Historic Review for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 253: South Korea 16-Year Perspective for Neurology Contract Research Organization by Service - Percentage Breakdown of Value Sales for Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance for the Years 2014, 2025 & 2030
    • TABLE 254: South Korea Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Indication - Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: South Korea Historic Review for Neurology Contract Research Organization by Indication - Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 256: South Korea 16-Year Perspective for Neurology Contract Research Organization by Indication - Percentage Breakdown of Value Sales for Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 257: South Korea Recent Past, Current & Future Analysis for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: South Korea Historic Review for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 259: South Korea 16-Year Perspective for Neurology Contract Research Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 260: South Korea Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: South Korea Historic Review for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 262: South Korea 16-Year Perspective for Neurology Contract Research Organization by Study - Percentage Breakdown of Value Sales for Neuroscience Focused Study and Neurology Focused Study for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 263: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Rest of Asia-Pacific Historic Review for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 265: Rest of Asia-Pacific 16-Year Perspective for Neurology Contract Research Organization by Service - Percentage Breakdown of Value Sales for Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance for the Years 2014, 2025 & 2030
    • TABLE 266: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Indication - Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Rest of Asia-Pacific Historic Review for Neurology Contract Research Organization by Indication - Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 268: Rest of Asia-Pacific 16-Year Perspective for Neurology Contract Research Organization by Indication - Percentage Breakdown of Value Sales for Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 269: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Rest of Asia-Pacific Historic Review for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 271: Rest of Asia-Pacific 16-Year Perspective for Neurology Contract Research Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 272: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Rest of Asia-Pacific Historic Review for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 274: Rest of Asia-Pacific 16-Year Perspective for Neurology Contract Research Organization by Study - Percentage Breakdown of Value Sales for Neuroscience Focused Study and Neurology Focused Study for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Neurology Contract Research Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 275: Latin America Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 276: Latin America Historic Review for Neurology Contract Research Organization by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 277: Latin America 16-Year Perspective for Neurology Contract Research Organization by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 278: Latin America Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Latin America Historic Review for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 280: Latin America 16-Year Perspective for Neurology Contract Research Organization by Service - Percentage Breakdown of Value Sales for Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance for the Years 2014, 2025 & 2030
    • TABLE 281: Latin America Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Indication - Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Latin America Historic Review for Neurology Contract Research Organization by Indication - Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 283: Latin America 16-Year Perspective for Neurology Contract Research Organization by Indication - Percentage Breakdown of Value Sales for Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 284: Latin America Recent Past, Current & Future Analysis for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Latin America Historic Review for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 286: Latin America 16-Year Perspective for Neurology Contract Research Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 287: Latin America Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Latin America Historic Review for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 289: Latin America 16-Year Perspective for Neurology Contract Research Organization by Study - Percentage Breakdown of Value Sales for Neuroscience Focused Study and Neurology Focused Study for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 290: Argentina Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Argentina Historic Review for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 292: Argentina 16-Year Perspective for Neurology Contract Research Organization by Service - Percentage Breakdown of Value Sales for Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance for the Years 2014, 2025 & 2030
    • TABLE 293: Argentina Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Indication - Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Argentina Historic Review for Neurology Contract Research Organization by Indication - Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 295: Argentina 16-Year Perspective for Neurology Contract Research Organization by Indication - Percentage Breakdown of Value Sales for Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 296: Argentina Recent Past, Current & Future Analysis for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Argentina Historic Review for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 298: Argentina 16-Year Perspective for Neurology Contract Research Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 299: Argentina Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Argentina Historic Review for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 301: Argentina 16-Year Perspective for Neurology Contract Research Organization by Study - Percentage Breakdown of Value Sales for Neuroscience Focused Study and Neurology Focused Study for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 302: Brazil Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Brazil Historic Review for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 304: Brazil 16-Year Perspective for Neurology Contract Research Organization by Service - Percentage Breakdown of Value Sales for Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance for the Years 2014, 2025 & 2030
    • TABLE 305: Brazil Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Indication - Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Brazil Historic Review for Neurology Contract Research Organization by Indication - Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 307: Brazil 16-Year Perspective for Neurology Contract Research Organization by Indication - Percentage Breakdown of Value Sales for Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 308: Brazil Recent Past, Current & Future Analysis for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Brazil Historic Review for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 310: Brazil 16-Year Perspective for Neurology Contract Research Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 311: Brazil Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Brazil Historic Review for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 313: Brazil 16-Year Perspective for Neurology Contract Research Organization by Study - Percentage Breakdown of Value Sales for Neuroscience Focused Study and Neurology Focused Study for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 314: Mexico Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Mexico Historic Review for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 316: Mexico 16-Year Perspective for Neurology Contract Research Organization by Service - Percentage Breakdown of Value Sales for Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance for the Years 2014, 2025 & 2030
    • TABLE 317: Mexico Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Indication - Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 318: Mexico Historic Review for Neurology Contract Research Organization by Indication - Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 319: Mexico 16-Year Perspective for Neurology Contract Research Organization by Indication - Percentage Breakdown of Value Sales for Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 320: Mexico Recent Past, Current & Future Analysis for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 321: Mexico Historic Review for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 322: Mexico 16-Year Perspective for Neurology Contract Research Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 323: Mexico Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 324: Mexico Historic Review for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 325: Mexico 16-Year Perspective for Neurology Contract Research Organization by Study - Percentage Breakdown of Value Sales for Neuroscience Focused Study and Neurology Focused Study for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 326: Rest of Latin America Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 327: Rest of Latin America Historic Review for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 328: Rest of Latin America 16-Year Perspective for Neurology Contract Research Organization by Service - Percentage Breakdown of Value Sales for Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance for the Years 2014, 2025 & 2030
    • TABLE 329: Rest of Latin America Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Indication - Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 330: Rest of Latin America Historic Review for Neurology Contract Research Organization by Indication - Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 331: Rest of Latin America 16-Year Perspective for Neurology Contract Research Organization by Indication - Percentage Breakdown of Value Sales for Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 332: Rest of Latin America Recent Past, Current & Future Analysis for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 333: Rest of Latin America Historic Review for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 334: Rest of Latin America 16-Year Perspective for Neurology Contract Research Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 335: Rest of Latin America Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 336: Rest of Latin America Historic Review for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 337: Rest of Latin America 16-Year Perspective for Neurology Contract Research Organization by Study - Percentage Breakdown of Value Sales for Neuroscience Focused Study and Neurology Focused Study for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Neurology Contract Research Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 338: Middle East Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 339: Middle East Historic Review for Neurology Contract Research Organization by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 340: Middle East 16-Year Perspective for Neurology Contract Research Organization by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 341: Middle East Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 342: Middle East Historic Review for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 343: Middle East 16-Year Perspective for Neurology Contract Research Organization by Service - Percentage Breakdown of Value Sales for Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance for the Years 2014, 2025 & 2030
    • TABLE 344: Middle East Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Indication - Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 345: Middle East Historic Review for Neurology Contract Research Organization by Indication - Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 346: Middle East 16-Year Perspective for Neurology Contract Research Organization by Indication - Percentage Breakdown of Value Sales for Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 347: Middle East Recent Past, Current & Future Analysis for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 348: Middle East Historic Review for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 349: Middle East 16-Year Perspective for Neurology Contract Research Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 350: Middle East Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 351: Middle East Historic Review for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 352: Middle East 16-Year Perspective for Neurology Contract Research Organization by Study - Percentage Breakdown of Value Sales for Neuroscience Focused Study and Neurology Focused Study for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 353: Iran Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 354: Iran Historic Review for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 355: Iran 16-Year Perspective for Neurology Contract Research Organization by Service - Percentage Breakdown of Value Sales for Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance for the Years 2014, 2025 & 2030
    • TABLE 356: Iran Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Indication - Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 357: Iran Historic Review for Neurology Contract Research Organization by Indication - Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 358: Iran 16-Year Perspective for Neurology Contract Research Organization by Indication - Percentage Breakdown of Value Sales for Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 359: Iran Recent Past, Current & Future Analysis for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 360: Iran Historic Review for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 361: Iran 16-Year Perspective for Neurology Contract Research Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 362: Iran Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 363: Iran Historic Review for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 364: Iran 16-Year Perspective for Neurology Contract Research Organization by Study - Percentage Breakdown of Value Sales for Neuroscience Focused Study and Neurology Focused Study for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 365: Israel Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 366: Israel Historic Review for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 367: Israel 16-Year Perspective for Neurology Contract Research Organization by Service - Percentage Breakdown of Value Sales for Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance for the Years 2014, 2025 & 2030
    • TABLE 368: Israel Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Indication - Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 369: Israel Historic Review for Neurology Contract Research Organization by Indication - Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 370: Israel 16-Year Perspective for Neurology Contract Research Organization by Indication - Percentage Breakdown of Value Sales for Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 371: Israel Recent Past, Current & Future Analysis for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 372: Israel Historic Review for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 373: Israel 16-Year Perspective for Neurology Contract Research Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 374: Israel Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 375: Israel Historic Review for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 376: Israel 16-Year Perspective for Neurology Contract Research Organization by Study - Percentage Breakdown of Value Sales for Neuroscience Focused Study and Neurology Focused Study for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 377: Saudi Arabia Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 378: Saudi Arabia Historic Review for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 379: Saudi Arabia 16-Year Perspective for Neurology Contract Research Organization by Service - Percentage Breakdown of Value Sales for Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance for the Years 2014, 2025 & 2030
    • TABLE 380: Saudi Arabia Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Indication - Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 381: Saudi Arabia Historic Review for Neurology Contract Research Organization by Indication - Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 382: Saudi Arabia 16-Year Perspective for Neurology Contract Research Organization by Indication - Percentage Breakdown of Value Sales for Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 383: Saudi Arabia Recent Past, Current & Future Analysis for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 384: Saudi Arabia Historic Review for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 385: Saudi Arabia 16-Year Perspective for Neurology Contract Research Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 386: Saudi Arabia Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 387: Saudi Arabia Historic Review for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 388: Saudi Arabia 16-Year Perspective for Neurology Contract Research Organization by Study - Percentage Breakdown of Value Sales for Neuroscience Focused Study and Neurology Focused Study for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 389: UAE Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 390: UAE Historic Review for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 391: UAE 16-Year Perspective for Neurology Contract Research Organization by Service - Percentage Breakdown of Value Sales for Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance for the Years 2014, 2025 & 2030
    • TABLE 392: UAE Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Indication - Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 393: UAE Historic Review for Neurology Contract Research Organization by Indication - Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 394: UAE 16-Year Perspective for Neurology Contract Research Organization by Indication - Percentage Breakdown of Value Sales for Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 395: UAE Recent Past, Current & Future Analysis for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 396: UAE Historic Review for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 397: UAE 16-Year Perspective for Neurology Contract Research Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 398: UAE Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 399: UAE Historic Review for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 400: UAE 16-Year Perspective for Neurology Contract Research Organization by Study - Percentage Breakdown of Value Sales for Neuroscience Focused Study and Neurology Focused Study for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 401: Rest of Middle East Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 402: Rest of Middle East Historic Review for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 403: Rest of Middle East 16-Year Perspective for Neurology Contract Research Organization by Service - Percentage Breakdown of Value Sales for Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance for the Years 2014, 2025 & 2030
    • TABLE 404: Rest of Middle East Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Indication - Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 405: Rest of Middle East Historic Review for Neurology Contract Research Organization by Indication - Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 406: Rest of Middle East 16-Year Perspective for Neurology Contract Research Organization by Indication - Percentage Breakdown of Value Sales for Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 407: Rest of Middle East Recent Past, Current & Future Analysis for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 408: Rest of Middle East Historic Review for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 409: Rest of Middle East 16-Year Perspective for Neurology Contract Research Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 410: Rest of Middle East Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 411: Rest of Middle East Historic Review for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 412: Rest of Middle East 16-Year Perspective for Neurology Contract Research Organization by Study - Percentage Breakdown of Value Sales for Neuroscience Focused Study and Neurology Focused Study for the Years 2014, 2025 & 2030
  • AFRICA
    • Neurology Contract Research Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 413: Africa Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 414: Africa Historic Review for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 415: Africa 16-Year Perspective for Neurology Contract Research Organization by Service - Percentage Breakdown of Value Sales for Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance for the Years 2014, 2025 & 2030
    • TABLE 416: Africa Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Indication - Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 417: Africa Historic Review for Neurology Contract Research Organization by Indication - Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 418: Africa 16-Year Perspective for Neurology Contract Research Organization by Indication - Percentage Breakdown of Value Sales for Alzheimer's Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 419: Africa Recent Past, Current & Future Analysis for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 420: Africa Historic Review for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 421: Africa 16-Year Perspective for Neurology Contract Research Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 422: Africa Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 423: Africa Historic Review for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 424: Africa 16-Year Perspective for Neurology Contract Research Organization by Study - Percentage Breakdown of Value Sales for Neuroscience Focused Study and Neurology Focused Study for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제